McGowan Institute for Regenerative Medicine faculty member Massimo Trucco, MD, is an international leader in the field of immunogenetics, having dedicated his life's work to finding a cure for diabetes. Dr. Trucco is the Director of the Division of Immunogenetics at the Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center, the Hillman Professor of Pediatric Immunology at Children's Hospital, and a Professor of Pediatrics at the University of Pittsburgh School of Medicine.
Dr. Trucco and his team are closing in on a cure for Type 1 diabetes. He has made several significant findings including the isolation of a super-antigen that is believed to trigger juvenile diabetes in children. It is widely suspected that this discovery, and others that Dr. Trucco has made, will lead to a cure.
- Introducing a Unique Recourse-FDA Related Guidance for Device Approvals
- March Special at the Histology Lab
- Biologic Scaffolds for Regenerative Medicine 8th Symposium
- Third Annual Regenerative Rehabilitation Symposium
- Regenerative Medicine Summer School
- Provost Inaugural Lecture: Dr. Peter Rubin
- Dr. Yadong Wang Named Fellow of AIMBE
- Dr. Anna Balazs Named Materials Research Society Fellow
Authors: Glowacki AJ, Yoshizawa S, Jhunjhunwala S, Vieira AE, Garlet GP, Sfeir C, Little SR.
Title: Prevention of inflammation-mediated bone loss in murine and canine periodontal disease via recruitment of regulatory lymphocytes.
Summary: The hallmark of periodontal disease is the progressive destruction of gingival soft tissue and alveolar bone, which is initiated by inflammation in response to an invasive and persistent bacterial insult. In recent years, it has become apparent that this tissue destruction is associated with a decrease in local regulatory processes, including a decrease of forkhead box P3-expressing regulatory lymphocytes. Accordingly, we developed a controlled release system capable of generating a steady release of a known chemoattractant for regulatory lymphocytes, C-C motif chemokine ligand 22 (CCL22), composed of a degradable polymer with a proven track record of clinical translation, poly(lactic-co-glycolic) acid. We have previously shown that this sustained presentation of CCL22 from a point source effectively recruits regulatory T cells (Tregs) to the site of injection. Following administration of the Treg-recruiting formulation to the gingivae in murine experimental periodontitis, we observed increases in hallmark Treg-associated anti-inflammatory molecules, a decrease of proinflammatory cytokines, and a marked reduction in alveolar bone resorption. Furthermore, application of the Treg-recruiting formulation (fabricated with human CCL22) in ligature-induced periodontitis in beagle dogs leads to reduced clinical measures of inflammation and less alveolar bone loss under severe inflammatory conditions in the presence of a diverse periodontopathogen milieu.
Source: Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18525-30. Epub 2013 Oct 28.
Project Description: The U.S. Army Medical Research and Materiel Command has announced the grants awarded under the Armed Forces Institute of Regenerative Medicine: Warrior Restoration Consortium, known as AFIRM-II.
The AFIRM II program is intended to continue the success of the original AFIRM program, which was first funded in 2008. AFIRM-I focused on limb repair, craniofacial repair, burn repair, scarless wound repair, and compartment syndrome. The AFIRM program emphasized getting projects through advanced development, so that the innovations could be used for patients who need them. During the first program, more than 180 patients received treatment with AFIRM-funded technologies.
AFIRM II is a multi-institution endeavor and will focus on five key areas, including extremity regeneration; craniomaxillofacial regeneration; skin regeneration; composite tissue allotransplantation and immunomodulation; and genitourinary/lower abdomen reconstruction. The goals of the program are to fund basic through translational regenerative medicine research, and to bring promising technologies and restorative practices into human clinical trials.
The leader of the Pittsburgh-based program is Rocky Tuan, PhD and the specific Pittsburgh-based projects are listed below:
- In Situ Influence of Cell Fate for Functional Soft Tissue Reconstruction; PI: Stephen Badylak, DVM, PhD, MD
- Novel Strategies for Repair and Restoration of Calvarial Bone Defects in Wounds Compromised by Infection and Scarring; PI: Joseph Losee, MD ; Co-PI: Phil Campbell, PhD (Carnegie Mellon)
- Biodegradable Conduits for Large Extremity Nerve Injuries; PI: Kacey
Newsletter Comments or Questions: McGowan@pitt.edu